Abstract
The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal–epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpression of the HGF, have been reported in a substantial subgroup of NSCLC patients resistant to EGFR-TKIs. Several cMET-inhibitors have been developed as potential therapeutic candidates, and are currently under investigation in clinical trials. These compounds include both monoclonal antibodies and TKIs, and most of them have been investigated as dual combinations including an anti-EGFR TKI, to improve the efficacy of the available treatments, and ultimately overcome acquired resistance to EGFR-inhibitors.
Keywords: cMET, cMET-Inhibitors, EGFR-TKIs resistance, HGF, NSCLC, targeted therapies.
Current Drug Targets
Title:The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Volume: 15 Issue: 14
Author(s): Francesco Passiglia, Nele Van Der Steen, Luis Raez, Patrick Pauwels, Ignacio Gil-Bazo, Edgardo Santos, Daniele Santini, Giovanni Tesoriere, Antonio Russo, Giuseppe Bronte, Karen Zwaenepoel, Federico Cappuzzo and Christian Rolfo
Affiliation:
Keywords: cMET, cMET-Inhibitors, EGFR-TKIs resistance, HGF, NSCLC, targeted therapies.
Abstract: The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal–epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpression of the HGF, have been reported in a substantial subgroup of NSCLC patients resistant to EGFR-TKIs. Several cMET-inhibitors have been developed as potential therapeutic candidates, and are currently under investigation in clinical trials. These compounds include both monoclonal antibodies and TKIs, and most of them have been investigated as dual combinations including an anti-EGFR TKI, to improve the efficacy of the available treatments, and ultimately overcome acquired resistance to EGFR-inhibitors.
Export Options
About this article
Cite this article as:
Passiglia Francesco, Steen Van Der Nele, Raez Luis, Pauwels Patrick, Gil-Bazo Ignacio, Santos Edgardo, Santini Daniele, Tesoriere Giovanni, Russo Antonio, Bronte Giuseppe, Zwaenepoel Karen, Cappuzzo Federico and Rolfo Christian, The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/138945011514141216092739
DOI https://dx.doi.org/10.2174/138945011514141216092739 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NK Cell Function in HIV-1 Infection
Current HIV Research The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Clinical Proteomics in Cancer Research
Current Proteomics Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets Synthesis and <i>In silico</i> Studies of Quinazolinone Derivatives as PARP-1 Inhibitors
Letters in Drug Design & Discovery Improving Safety of Gene Therapy
Current Drug Safety Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Subject Index to Volume 7
Combinatorial Chemistry & High Throughput Screening ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship
Current Medical Imaging Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction
Current Cancer Drug Targets Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers
Current Cancer Drug Targets Plumbagin: A Potential Anti-cancer Compound
Mini-Reviews in Medicinal Chemistry Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Interleukin 20
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism The Diagnostic Utility of Pleural Fluid Tests in Clinical Practice
Current Respiratory Medicine Reviews